Immunological basis for the therapy of multiple sclerosis.
Much progress is currently being made in different areas of clinical and experimental multiple sclerosis (MS) research, including epidemiology and genetics, immunological mechanisms, possible role of infectious agents, imaging, clinical trials and development of new therapeutic agents. This article reviews some principles of MS pathogenesis and immunotherapy.
Hohlfeld
R
R
Department of Neurology, Klinikum Grosshadern, University of Munich, Germany.
D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000209:etiology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use; D011108:Polymers
D007166:Immunosuppressive Agents; D010455:Peptides; D011108:Polymers; D000068717:Glatiramer Acetate; D007372:Interferons